Search Results 221-230 of 17319 for Cyclophosphamide

1. Tisagenlecleucel (intravenous route) - Side effects & uses - Mayo Clinic

   ... cyclophosphamide, bendamustine). You should stay close to the hospital or center to check for unwanted effects for at least 2 weeks receiving this medicine ...

2. Breast Cancer Surgery Clinical Trials - Mayo Clinic Research

   Drugs used in chemotherapy, such as docetaxel, doxorubicin, cyclophosphamide, paclitaxel, and gemcitabine work in different ways to stop tumor cells from ...

3. A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis (Cielo) - Mayo Clinic

   * Treatment with oral cyclophosphamide within 1 year prior to baseline Treatment with any investigational drug (including bortezomib) within 24 weeks prior ...

4. Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma - Mayo Clinic

   Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the ...

5. Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer, the ENHANCE Study - Mayo Clinic

   ... cyclophosphamide (Cytoxan) (A/C) Non-anthracycline;; TCH +/- P (docetaxel, carboplatin, trastuzumab +/- pertuzumab);; TH +/- P (paclitaxel, trastuzumab +/- ...

6. Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa) - Mayo Clinic

   Prior to bb2121 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide. Participation eligibility. Participant ...

7. Study of Dexamethasone Plus IXAZOMIB or Physician's Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis - Mayo Clinic

   Treatment options will include: dexamethasone alone, dexamethasone plus an alkylating agent (melphalan or cyclophosphamide), or dexamethasone plus an ...

8. Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma - Mayo Clinic

   The purpose of this study is to investigate how well modified VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and ...

9. A Study to Assess Older Adults Applying Pre-transplant Comorbidity, Geriatric Assessment and Biomarkers to Predict Non-Relapse Mortality After Allogeneic Transplant (CHARM) - Mayo Clinic

   ... cyclophosphamide followed by cyclosporine A and mycophenolate mofetil, whereas patients in other groups received pretransplantation antithymocyte globulin ...

10. Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release - Mayo Clinic

    History of hypersensitivity to cyclophosphamide, mesna, fludarabine, or any component of lifileucel cryopreservation medium; Ongoing systemic infection ...